JP2023055802A5 - - Google Patents

Download PDF

Info

Publication number
JP2023055802A5
JP2023055802A5 JP2023010846A JP2023010846A JP2023055802A5 JP 2023055802 A5 JP2023055802 A5 JP 2023055802A5 JP 2023010846 A JP2023010846 A JP 2023010846A JP 2023010846 A JP2023010846 A JP 2023010846A JP 2023055802 A5 JP2023055802 A5 JP 2023055802A5
Authority
JP
Japan
Prior art keywords
human
status epilepticus
ylmethylphosphonofluoridate
midazolam
povidone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023010846A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023055802A (ja
Filing date
Publication date
Priority claimed from PCT/US2018/049515 external-priority patent/WO2019050923A1/en
Application filed filed Critical
Publication of JP2023055802A publication Critical patent/JP2023055802A/ja
Publication of JP2023055802A5 publication Critical patent/JP2023055802A5/ja
Pending legal-status Critical Current

Links

JP2023010846A 2017-09-05 2023-01-27 ダントロレンを使用して神経薬暴露を治療する方法 Pending JP2023055802A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762554049P 2017-09-05 2017-09-05
US62/554,049 2017-09-05
US201862674406P 2018-05-21 2018-05-21
US62/674,406 2018-05-21
PCT/US2018/049515 WO2019050923A1 (en) 2017-09-05 2018-09-05 METHODS OF USING DANTROLENE TO TREAT EXPOSURE TO A NEUROTOXIC AGENT
JP2020512813A JP2020532555A (ja) 2017-09-05 2018-09-05 ダントロレンを使用して神経薬暴露を治療する方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020512813A Division JP2020532555A (ja) 2017-09-05 2018-09-05 ダントロレンを使用して神経薬暴露を治療する方法

Publications (2)

Publication Number Publication Date
JP2023055802A JP2023055802A (ja) 2023-04-18
JP2023055802A5 true JP2023055802A5 (https=) 2023-07-28

Family

ID=63708449

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020512813A Pending JP2020532555A (ja) 2017-09-05 2018-09-05 ダントロレンを使用して神経薬暴露を治療する方法
JP2023010846A Pending JP2023055802A (ja) 2017-09-05 2023-01-27 ダントロレンを使用して神経薬暴露を治療する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020512813A Pending JP2020532555A (ja) 2017-09-05 2018-09-05 ダントロレンを使用して神経薬暴露を治療する方法

Country Status (15)

Country Link
US (2) US20200383954A1 (https=)
EP (1) EP3678659B1 (https=)
JP (2) JP2020532555A (https=)
KR (1) KR20200047655A (https=)
CN (1) CN111093652A (https=)
AU (1) AU2018328131B2 (https=)
BR (1) BR112020004429A2 (https=)
CA (1) CA3074732A1 (https=)
IL (1) IL272847B1 (https=)
MA (1) MA50080A (https=)
MX (2) MX2020002485A (https=)
SG (1) SG11202001749SA (https=)
UA (1) UA126688C2 (https=)
WO (1) WO2019050923A1 (https=)
ZA (1) ZA202001258B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022538608A (ja) * 2019-06-28 2022-09-05 ザ トラスティーズ オヴ ザ ユニヴァーシティー オヴ ペンシルバニア アルツハイマー病の治療のための鼻腔内ダントロレン投与
WO2023081873A1 (en) * 2021-11-05 2023-05-11 Quorum Innovations, Llc Materials and methods for preventing or reducing toxicity to organophosphates and other toxic materials

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7758890B2 (en) * 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
EP1603513B1 (en) * 2003-03-04 2020-12-30 Lyotropic Therapeutics, Inc. Dantrolene compositions
WO2013040501A1 (en) * 2011-09-16 2013-03-21 Pharmathene, Inc. Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
DK2925327T3 (da) * 2012-11-30 2024-03-25 Univ California Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression

Similar Documents

Publication Publication Date Title
JP2023055802A5 (https=)
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
Gayraud Raynaud's phenomenon
JP2019503365A5 (https=)
JP2022191257A5 (https=)
JP2024133474A5 (https=)
JPWO2021121367A5 (https=)
JP2021529829A5 (https=)
JP2025092508A5 (https=)
JP2024133717A5 (https=)
HRP20120798T1 (hr) Kappa-opijatni agonisti za lijeäśenje dijareja-predominantnog i naizmjeniäśnog sindroma iritabilnog crijeva
JP2022163049A5 (https=)
EA202190544A1 (ru) Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
JP2019089796A5 (https=)
JP2005507892A5 (https=)
JP2020529995A5 (https=)
JPWO2020257671A5 (https=)
JPWO2020257665A5 (https=)
JP2004525940A5 (https=)
JP2002326936A5 (https=)
JPWO2020000092A5 (https=)
JP2008533079A5 (https=)
AR114006A1 (es) Combinación farmacéutica en la forma de comprimidos en bicapa que comprende ketorolaco trometamina y tramadol clorhidrato, y su uso para el tratamiento del dolor
JPWO2022076818A5 (https=)
JP2019099579A5 (https=)